Precision Cancer Therapy in Rare Cancers

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

NCT Number	NCT06119789
Lead Sponsor	Oslo University Hospital Collaborators: Helse Stavanger HF, University Hospital of North Norway, StOlavs Hospital, Nordlandssykehuset HF, Helse Nord-Trøndelag HF, Sorlandet Hospital HF, Møre og Romsdal Hospital Trust, The Hospital of Vestfold, Helse Fonna, Haukeland University Hospital, Sykehuset Ostfold, Helse Forde, Sykehuset Innlandet HF
Conditions	Rare Malignant Neoplasm
Enrollment	96 participants
Start Date	2025-03-20
Primary Completion	2033-11-30 (estimated)
Study Completion	2036-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-26